Emerging Therapies in Multiple Myeloma
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cancer Research,Oncology
Reference35 articles.
1. How I treat multiple myeloma in younger patients.;Stewart;Blood,2009
2. Recent major improvement in long-term survival of younger patients with multiple myeloma.;Brenner;Blood,2008
3. . Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.;Demo;Cancer Res,2007
4. . Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma.;Jain;Core Evid,2011
5. . Proteasome inhibitors in multiple myeloma: 10 years later.;Moreau;Blood,2012
Cited by 24 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Urine immunofixation electrophoresis and serum free light chain analyses benefit diagnosis of multiple myeloma in orthopedic patients with normal serum total proteins, creatinine, calcium, and hemoglobin;Laboratory Medicine;2023-12-23
2. Use of the European Organisation for Research and Treatment of Cancer multiple myeloma module (EORTC QLQ-MY20): a review of the literature 25 years after development;Blood Cancer Journal;2023-05-16
3. Serum free light chains benefit diagnosis of multiple myeloma in orthopaedic patients with normal serum total proteins, creatinine, calcium and hemoglobin;2023-01-20
4. Diagnostic and therapeutic potential of protease inhibition;Molecular Aspects of Medicine;2022-12
5. Trust and shared decision‐making among individuals with multiple myeloma: A qualitative study;Cancer Medicine;2021-10-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3